Week 34 ACR20 response rates were comparable between the CZP 200 mg every 2 weeks and the 400 mg every 4 weeks groups ( 67.1 % versus 65.2 % ) , which was significantly higher than placebo ( 44.9 % ; P = 0.009 and P = 0.017 ) .